TITLE

"Flora Power" -- Fecal Bacteria Cure Chronic C. difficile Diarrhea

AUTHOR(S)
Borody, Thomas J.
PUB. DATE
November 2000
SOURCE
American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3028
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Discusses various research that focuses on the effect of human fecal flora bacteria in eradicating Clostridium difficile diarrhea. Factors to be considered in using the fecal flora therapy; Information on the flora bacteria; Use of the fecal flora treatment.
ACCESSION #
17628216

 

Related Articles

  • Fecal Transplantation for the Treatment of Recurrent Clostridium Difficile Infection. Karadsheh, Zeid; Sule, Sachin // North American Journal of Medical Sciences;Jun2013, Vol. 5 Issue 6, p339 

    Clostridium difficile infection (CDI) is currently a leading cause of antibiotic and health care-related diarrhea. The incidence and the severity of CDI-related diarrhea have increased dramatically in the USA and Europe in the past few decades. The emergence of multidrug-resistant hypervirulent...

  • Getting “C diff” under control.  // RN;Apr2004 Supplement, Vol. 67, p19 

    Focuses on the treatment and newly developed therapeutics for treating Clostridium difficile. Role of C. difficile in causing antibiotic-associated diarrhea; Risk for immunocompromised patients to develop the infection; Characteristic of the organism. INSET: Bacterial invasion of the gut wall...

  • Dijareja izazvana Clostridium difficile kod bolesnika sa postoperativnim suphepatičnim apscesom. Stojanović, Predrag; Kocić, Branislava // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Mar2008, Vol. 65 Issue 3, p249 

    Background. Toxigenic strains of Clostridium difficile in the majority of cases cause disease of the intestinal tract of hospitalized patients. For a long time, Clostridium difficile was considered to produce both types of toxins (A+/B+ strain), however, the investigations conducted in the last...

  • Clostridium difficile and the Consequences of Progress. Sepkowitz, Kent A. // Journal of Oncology Practice;Jan2017, Vol. 13 Issue 1, p33 

    The article presents information on the condition and treatment of Clostridium difficile. Topics include the article "Clostridium difficile-associated Diarrhea in the Oncology Patient" by K. Neemann and A. Freifeld published in the "Journal of Oncology Practice" in 2017, the C difficile as the...

  • Bug bulletin: Clostridium difficile.  // Dental Nursing;Mar2009, Vol. 5 Issue 3, p152 

    The article offers information about the bacterium Clostridium difficile. It discusses the symptoms when diagnosing C. difficile, including diarrhea, antibiotic pressure and abdominal pain. It also explores the methods of treating cases of C. difficile, such as pharmacotherapy, faecal...

  • Clostridium difficile infection: Managing the risks. DeDea, Larissa // JAAPA: Journal of the American Academy of Physician Assistants (;May2012, Vol. 25 Issue 5, p16 

    The article offers information on how to manage the risks of Clostridium (C) difficile infections with proton pump inhibitors (PPIs) and probiotics in the U.S. It notes the association between C difficile infection and implicated antibiotic use and its mechanism with PPIs to gastric acid...

  • Community-acquired C. difficile diarrhea.  // Patient Care;5/15/1994, Vol. 28 Issue 9, p161 

    Highlights the study `Epidemiology of community-acquired Clostridium difficile-associated diarrhea,' by LR Hirschhorn and others from the `Journal of Infectious Diseases.' Association between Clostridium difficile infection and antibiotic use; Occurrence of C. difficile-associated diarrhea.

  • Diagnostic and Therapeutic Considerations for Oncology Patients With Clostridium difficile Infection. Woodworth, Michael H.; Kraft, Colleen S. // Journal of Oncology Practice;Jan2017, Vol. 13 Issue 1, p31 

    The article presents information on the diagnosis and treatment of oncology patients with Clostridium difficile infection. Topics include the article "Clostridium difficile-associated Diarrhea in the Oncology Patient" by K. Neemann and A. Freifeld published in the "Journal of Oncology Practice"...

  • Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole. Abujamel, Turki; Cadnum, Jennifer L.; Jury, Lucy A.; Sunkesula, Venkata C. K.; Kundrapu, Sirisha; Jump, Robin L.; Stintzi, Alain C.; Donskey, Curtis J. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background:Clostridium difficile is an anaerobic, spore-forming bacterium that is the most common cause of healthcare-associated diarrhea in developed countries. A significant proportion of patients receiving oral vancomycin or metronidazole for treatment of Clostridium difficile infection (CDI)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics